Recent News: Do Beta Adrenoceptor Blocking Agents Provide the Same Degree of Clinically Convincing Morbidity and Mortality Benefits in Patients with Chronic Heart Failure


Chronic heart has been extensively characterized as a disorder arising from a complex interaction between impaired ventricular performance and neurohormonal activation. Activation of the sympathetic nervous system is one of the key pathophysiological disturbances in patients with chronic heart failure. Levels of circulating catecholamine's increase in patients with heart failure which is directly proportional to the severity of the disease; and those with the highest plasma levels of norepinephrine have the most unfavorable prognosis. Sympathetic activation is a significant predictor of poor prognosis in patients with chronic heart failure. There is an overwhelming evidence that supports the notion that, drugs interfering with the neurohormonal activation (including sympathetic activation) in chronic heart failure not only produce symptomatic relief ; but are also capable of attenuating disease progression, with concomitant reductions in both morbidity and mortality.

Beta adrenoceptor blocking agents which antagonize the effects of the activated sympathetic nervous system have been shown to be beneficial in the long term in moderate to severe chronic heart failure in terms of significant improvements in both morbidity and mortality. Several well designed clinical trials have been conducted to determine the beneficial effects of beta adrenoceptor blocking agents on morbidity and mortality in chronic heart failure patients.

Journal of Cardiovascular Medicine and Therapy is a peer-reviewed, Open access scientific journal with an aim to provide rapid and reliable source of information on current discoveries and current developments in the field of cardiovascular focuses on following topics Atherosclerosis, Heart Attack, Ischemic Stroke, Cardiac ischemia, Plaque Attacks, Heart failure, Arrhythmia, Bradycardia, Tachycardia, etc.

Our esteemed journal is looking forward for the upcoming issue (Volume3: Issue1) for the upcoming year as all the authors are invited to submit their recent scientific work through manuscripts in the mode of Research/Case Reports/Case Studies/Reviews/Short Review/ Short Communications/Commentaries/Short Commentaries/Letters to Editor/ Image articles etc.

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System or as email attachment to:


Samuel G,
Editorial Manager,
Journal of Cardiovascular Medicine and Therapy